Human Stem Cell Institute and Xenetic Biosciences were the initiators of a major cross-border M&A transaction to form SynBio, with additional financing secured from Russia’s State Venture Fund Rusnano.
The two companies intend to pursue opportunities to extend their cooperation both within and beyond SynBio.
Xenetic Biosciences CEO Scott Maguire said Xenetic and the Human Stem Cell Institute, with their recently announced deals, are at the forefront of creating a new class of drug candidates.